ReviewBritish journal of pharmacology2013
To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma.
Review in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Macrophage-derived IL-1β directs fibroblast progenitor cell fate via metabolic reprogramming in wound healing.Communications biology · 2025Article
- Hematopoietic stem cell metabolism within the bone marrow niche - insights and opportunities.BioEssays : news and reviews in molecular, cellular and developmental biology · 2025Review
- "Time Is out of Joint" in Pluripotent Stem Cells: How and Why.International journal of molecular sciences · 2024Review
- Bioenergetic profile and redox tone modulate in vitro osteogenesis of human dental pulp stem cells: new perspectives for bone regeneration and repair.Stem cell research & therapy · 2023Article
- Myoglobin expression by alternative transcript in different mesenchymal stem cells compartments.Stem cell research & therapy · 2022Article
- Role of Copper on Mitochondrial Function and Metabolism.Frontiers in molecular biosciences · 2021Review
- Nandrolone induces a stem cell-like phenotype in human hepatocarcinoma-derived cell line inhibiting mitochondrial respiratory activity.Scientific reports · 2020Article
- Erythroid Differentiation and Heme Biosynthesis Are Dependent on a Shift in the Balance of Mitochondrial Fusion and Fission Dynamics.Frontiers in cell and developmental biology · 2020Article
- Neutrophil Metabolic Shift during their Lifecycle: Impact on their Survival and Activation.International journal of molecular sciences · 2019Review
- Divide and conquer: two stem cell populations in squamous epithelia, reserves and the active duty forces.International journal of oral science · 2019Review
- Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.Stem cell research & therapy · 2019Article
- Mitochondrial Role in Stemness and Differentiation of Hematopoietic Stem Cells.Stem cells international · 2019Review
- A metabolic interplay coordinated by HLX regulates myeloid differentiation and AML through partly overlapping pathways.Nature communications · 2018Article
- Hematopoietic stem cell fate through metabolic control.Experimental hematology · 2018Review
- Metabolism and the Control of Cell Fate Decisions and Stem Cell Renewal.Annual review of cell and developmental biology · 2016Review
- Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation.Molecular pharmacology · 2016Article
- An MTCH2 pathway repressing mitochondria metabolism regulates haematopoietic stem cell fate.Nature communications · 2015Article
- Critical Roles of Reactive Oxygen Species in Age-Related Impairment in Ischemia-Induced Neovascularization by Regulating Stem and Progenitor Cell Function.Oxidative medicine and cellular longevity · 2015Review
- The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy.Cell cycle (Georgetown, Tex.) · 2014Article
- Emerging therapeutic aspects in oncology.British journal of pharmacology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledAdult haematopoietic stem/progenitor cells (HSPCs) constitute the lifespan reserve for the generation of all the cellular lineages in the blood. Although massive progress in identifying the cluster of master genes controlling self-renewal and multipotency has been achieved in the past decade, some aspects of the physiology of HSPCs still need to be clarified. In particular, there is growing interest in the metabolic profile of HSPCs in view of their emerging role as determinants of cell fate. Indeed, stem cells and progenitors have distinct metabolic profiles, and the transition from stem to progenitor cell corresponds to a critical metabolic change, from glycolysis to oxidative phosphorylation. In this review, we summarize evidence, reported in the literature and provided by our group, highlighting the peculiar ability of HSPCs to adapt their mitochondrial oxidative/bioenergetic metabolism to survive in the hypoxic microenvironment of the endoblastic niche and to exploit redox signalling in controlling the balance between quiescence versus active cycling and differentiation. Especial prominence is given to the interplay between hypoxia inducible factor-1, globins and NADPH oxidases in managing the mitochondrial dioxygen-related metabolism and biogenesis in HSPCs under different ambient conditions. A mechanistic model is proposed whereby 'mitochondrial differentiation' is a prerequisite in uncommitted stem cells, paving the way for growth/differentiation factor-dependent processes. Advancing the understanding of stem cell metabolism will, hopefully, help to (i) improve efforts to maintain, expand and manipulate HSPCs ex vivo and realize their potential therapeutic benefits in regenerative medicine; (ii) reprogramme somatic cells to generate stem cells; and (iii) eliminate, selectively, malignant stem cells. LINKED ARTICLES: This article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue-8.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.